Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jul;7(3):234-50.
doi: 10.2174/187152509789105444.

Human plasma kallikrein-kinin system: physiological and biochemical parameters

Affiliations
Review

Human plasma kallikrein-kinin system: physiological and biochemical parameters

J W Bryant et al. Cardiovasc Hematol Agents Med Chem. 2009 Jul.

Abstract

The plasma kallikrein-kinin system (KKS) plays a critical role in human physiology. The KKS encompasses coagulation factor XII (FXII), the complex of prekallikrein (PK) and high molecular weight kininogen (HK). The conversion of plasma prekallikrein to kallikrein by the activated FXII and in response to numerous different stimuli leads to the generation of bradykinin (BK) and activated HK (HKa, an antiangiogenic peptide). BK is a proinflammatory peptide, a pain mediator and potent vasodilator, leading to robust accumulation of fluid in the interstitium. Systemic production of BK, HKa with the interplay between BK bound-BK receptors and the soluble form of HKa are key to angiogenesis and hemodynamics. KKS has been implicated in the pathogenesis of inflammation, hypertension, endotoxemia, and coagulopathy. In all these cases increased BK levels is the hallmark. In some cases, the persistent production of BK due to the deficiency of the blood protein C1-inhibitor, which controls FXII, is detrimental to the survival of the patients with hereditary angioedema (HAE). In others, the inability of angiotensin converting enzyme (ACE) to degrade BK leads to elevated BK levels and edema in patients on ACE inhibitors. Thus, the mechanisms that interfere with BK liberation or degradation would lead to blood pressure dysfunction. In contrast, anti-kallikrein treatment could have adverse effects in hemodynamic changes induced by vasoconstrictor agents. Genetic models of kallikrein deficiency are needed to evaluate the quantitative role of kallikrein and to validate whether strategies designed to activate or inhibit kallikrein may be important for regulating whole-body BK sensitivity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare that they have no competing interests or financial or otherwise.

Figures

Figure 1
Figure 1
classical coagulation cascade. The blood coagulation cascade consists of an extrinsic and intrinsic pathway. Both pathways results in activation of factor X, which subsequently converts prothrombin to thrombin. The coagulation cascade is a starting point for both the kallikrein-kinin system (KKS) and the complement system. Activation is indicated by solid arrows and inhibition by dotted arrows.
Figure 2
Figure 2
Amplification loops. The amplification loops associated with the coagulation cascade. The contact and intrinsic pathways make up the main amplification loops in the coagulation cascade. Activation is indicated by (+) and inhibition by (−).

References

    1. Hooley E, McEwan PA, Emsley J. J Thromb Haemost. 2007;5(12):2461. - PubMed
    1. Shariat-Madar Z, Schmaier AH. Trends Cardiovasc Med. 1999;9:238–44. - PubMed
    1. Tait JF, Fujikawa K. J Biol Chem. 1987;262:11651–56. - PubMed
    1. Thompson RE, Mandle R, Jr, Kaplan AP. J Clin Invest. 1977;60:1376–80. - PMC - PubMed
    1. Colman RW, Schmaier AH. Crit Rev Oncol Hematol. 1986;5:57–85. - PubMed